Merck & Co.

Summary

Industry
Operating Income
7,453,900,000 (2006-12-31, US$)
Revenue
22636000000.0 (2006-12-31, US$)
32714000000.0 (2000, US$)
22636000000.0 (2007, US$)
Number of employees
61,500 (2005)
Employees and other personnel
James Li (Medical director, China Operations, 1996, 2000)
James Li (Regional Marketing Director, Hypertension- Asia, 2003)
Date founded
1889
Headquarters
One Merck Drive (Whitehouse Station, NJ, 8,889)
ONE MERCK DR (P O BOX 100, Whitehouse, 8,889, New Jersey)
 

Business Operation

Net profit
4,632,000,000 (2005, US$)
5,890,500,000 (2000, US$)
4,433,800,000 (2007, US$)
Total Assets
47195700000.0 (2008-12-31, US$)
Total Liabilities
28437400000.0 (2008-12-31, US$)
Competitive space
Diabetic Neuropathy Treatment
Lateral Sclerosis Treatment
Cancer treatment
Current Assets
19304900000.0 (2008-12-31, US$)
Current Liabilities
14318700000.0 (2008-12-31, US$)
Cash
4,368,300,000 (2008-12-31, US$)
Retained Earnings
43698800000.0 (2008-12-31, US$)
 

Issuer

Issue
 

Ranked item

Appears in ranked lists
Fortune 1000 (95, 2006)
Fortune 1000 (103, 2009)
Fortune 1000 (101, 2008)
 

Customer

Supplier
 

Consumer company

Products
 

Drug manufacturer

Drugs manufactured
Cancidas 5 lyophilized powder for injectable solution (Cancidas, United States of America, no, 2001-01-26, 2015-07-26, 2010-06-01, dailymed.nlm.nih.gov, NDA021227, no, 0006-3822)
Singulair 5 chewable tablet (Singulair, United States of America, no, 1998-02-20, US Patent 5565473, 2012-08-03, Montelukast sodium 5 chewable tablet, 2012-03-26, Pink, Circle, 10, 1, MSD;275;SINGULAIR, dailymed.nlm.nih.gov, NDA020830, no, 0006-9275, Cherry)
Isentress 25 chewable tablet (Raltegravir, United States of America, no, 2011-12-21, US Patent 7754731, 2029-03-11, 2012-03-28, Yellow, Circle, 8, 1, Merck;logo;473, dailymed.nlm.nih.gov, NDA203045, no, 0006-0473)
 

BV: Venture Investor

Investment Round
Burrill & Company, HBM BioVentures AG, HealthCap (2008-10-08, Odyssey Thera)
 

Publisher

Book editions published
 

Author

Works written
 

Organization

Legal structure
Place founded
Organizations acquired
Schering-Plough (2009-11)
Founders
Board members
Richard T. Clark (2007, Chair)
Peter Wendell (2003)
Spun off from
Merck KGaA (1917)
Spin offs
Child
Merial Korea Ltd (2005, 2006, 2007, 2008, 2009)
Merck Frosst Canada Ltd (2004, 2005, 2006, 2007, 2008, 2009)
Merck HDAC Research LLC (2007, 2008, 2009)
Leadership
Exec. V.P. & C.F.O (Peter N. Kellogg, 2009)
Exec. V-P and Pres., MRL (Peter S. Kim, 2009)
Vice President and Treasurer (Mark E Mcdonough, 2009)
Phone number
 

Science or Technology Company

Medical focus
Products
Technology Focus
 

Architectural structure owner

Structures Owned
Edit this page

Freebase CC-BY
Source: Merck & Co. on Freebase licensed under CC-BY
Georg-Merck-sen..png by Freebase NSTK by Flickr user graafik